Abstract This study aimed to determine whether dosedense therapy improves 3-year survival over the standard therapy for untreated aggressive lymphoma. One hundred and fifteen patients with untreated aggressive lymphoma were stratified by center, age, and international prognostic index and randomized to one of two treatment arms. One hundred and three were eligible. The experimental dosedense arm consisted of weekly therapy with cyclophosphamide, epirubicine, vincristine, prednisolone, ifosfamide, etoposide, methotrexate, dexamethasone, and filgrastim (CEOP/IMVP-Dexa). The standard arm consisted of threeweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The primary endpoint was overall survival after 3 years. Overall survival at 3 years was 0. ClinicalTrials.gov registration no. NCT00517894
Introduction
The cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) polychemotherapy regimen was the first therapy to cure aggressive non-Hodgkin's lymphoma [7] . With this therapy, the overall survival of patients is 52% at short-term follow-up, but long-term remissions occur in less than 30% of patients [9, 17] . Therefore, more efficient therapies are urgently needed.
Several treatment regimens using more than four drugs, based on the Goldie-Coldman hypothesis [13] of using more effective drugs early in treatment to avoid resistance, improved survival when tested in single-center, phase II studies. However, in randomized trials, these regimens proved to be more toxic than CHOP [8] . Problems with patient selection may be the major reason why these newer regimens had inferior outcome in the randomized trial despite promising results in the phase II trials. Additionally, increasing the number of drugs in a treatment regimen usually results in a dose reduction of the key drugs cyclophosphamide and anthracycline. This may also explain the failure of these newer regimens.
The concept of dose density is the application of cytotoxic drugs in short intervals to target the malignant cells during the phase of rapid regrowth after the last treatment. The cyclophosphamide, epirubicine, vincristine, prednisolone, ifosfamide, etoposide, methotrexate, dexamethasone, and filgrastim (CEOP/IMVP-Dexa) is a dose-dense regimen, with weekly administration of cytotoxic drugs. The dose of anthracyline and cyclophosphamide was not reduced compared to CHOP. To avoid excessive myelotoxicity, we alternated myelotoxic and less myelotoxic drugs and used prophylactic filgrastim. The regimen proved to be safe and effective in earlier trials of the Austrian Working Party for Medical Tumor Therapy (AGMT) with an overall survival of 0.583 after 8 years [11] . In this study, we tested the hypothesis that dose-dense therapy results in better survival than CHOP in patients with untreated aggressive lymphoma.
Patients and methods
This study (NHL-5) was a prospective, multicenter, randomized phase III study of the AGMT. The study was reviewed by the ethics committees at each participating institution and was performed according to the Declaration of Helsinki. Central randomization was done using by a computer method; patients were stratified by center, international prognostic index (IPI) [1] , and age. All patients gave written informed consent before entry.
The primary endpoint was survival after 3 years. The secondary endpoints were survival after 5 years, time to treatment failure after 3 and 5 years, remission rate, and toxicity.
Between February 1995 and September 2001, 115 patients were randomized. Patients between 18 and 70 years of age and with centrally reviewed, histologically confirmed diffuse large B cell, anaplastic large-cell lymphoma, or peripheral T cell lymphoma unspecified, measurable disease, in all stages, were included in the study. Patients with lymphoblastic or Burkitt histology, CNS disease, HIV-positive patients, pregnant or lactating women, pretreatment, other malignancy, or concomitant diseases that precluded chemotherapy were excluded from the study.
Treatment
The dose-dense therapy (CEOP/IMVP-Dexa) was provided as previously described [10, 12] 19) , and methotrexate (800 mg/m 2 i.v. day22) were used. Mesna uroprotection was given after ifosfamide and calcium folinate rescue after methotrexate. Filgrastim was given on days2-7, 9-12, 18-21, and 23-28. Chemotherapy doses were maintained unless neutrophil counts fell below 1.0 G/L. If neutrophil counts fell between 1.0 and 0.2 G/L, doses were reduced to 50%. If neutrophil counts were 0.2 G/L or lower, chemotherapy was delayed for 1 week. In patients with infections, chemotherapy was delayed until recovery. Antibiotic prophylaxis was not used. Patients 60 years of age or older had a 20% dose reduction for all cytostatic drugs.
In the experimental dose-dense arm, two to four cycles of CEOP/IMVP-Dexa was given to reach a complete remission (CR). Patients who did not achieve a partial remission (PR) after two cycles or a CR after four cycles were removed from the study and treated at the discretion of the treating physician. Patients achieving a CR received two consolidation cycles after achieving the CR (Fig. 1) In the standard arm, three-weekly CHOP was given as described earlier [7] . Three to six cycles were given to reach a CR. Patients who did not reach a PR after three cycles or a CR after six cycles were removed from the study and treated at the discretion of the treating physician. Patients achieving a CR received three consolidation cycles after achieving the CR (Fig. 1) . The number of treatment cycles depended on how quickly the patient responded to the treatment. In patients with one to five cycles in the CHOP arm or one to three cycles in the dose-dense arm the treatment was stopped because of progression, toxicity, or early death ( Figs. 1 and 2 ).
Biostatistics
All eligible patients were included in the analysis. Survival estimates were obtained by the Kaplan-Meier method [16] . The log-rank test was used to compare survival between the two arms. Unadjusted hazard ratios were estimated by the COX regression [6] . The patient characteristics, side effects, and remission rates were compared using the t test, To detect an estimated improvement in the 3-year survival from 0.54 to 0.72 with a power of 80% and an alpha-error of 0.05 in a one-sided test, at least 50 patients per study arm were required. We chose a one-sided test because we were only interested in determining if dosedense therapy was better than CHOP.
CR, complete remission undetermined (CRu), PR, no change, progression, time to relapse, and time to treatment failure (TTF) were defined according to Cheson et al. [4] . Thus, survival includes all eligible patients and counts all deaths as events. TTF is the time from registration until relapse, progression, toxic death, withdrawal, or date last known to be alive, excluding deaths from unrelated causes.
Toxicity
Toxicity was assessed before each chemotherapy dose and whenever the patient visited the outpatient clinic using the WHO toxicity criteria (http://www.fda.gov/cder/cancer/ toxicityframe.htm). Patients randomized to the dosedense arm had weekly visits, while those in the CHOP arm were seen at 3-week intervals. In order to avoid differences resulting from the different evaluation intervals in the two arms, only the most severe toxicity during the whole therapy was considered.
Results

Patients
Between February 1995 and September 2001, 115 patients were enrolled; 52 were randomized into the dose-dense arm, and 51 were randomized into the CHOP arm. Seven patients were excluded from the dose-dense arm and five from the CHOP arm. Most of the exclusions were due to histology. In the dose-dense arm, two patients were excluded because no data were received from the treatment center, and one was excluded due to CNS involvement at diagnosis (Fig. 2) . The patient characteristics were comparable in both arms ( Table 1 ). The median observation time for surviving patients was 62.5 months.
Survival and treatment after relapse Dose-dense therapy was advantageous in terms of overall survival. Overall survival at 3 years was 0.766 (95% CI 0.6247, 0.8598) in the dose-dense arm and 0.462 (95% CI 0.3200, 0.5925) in the CHOP arm. Overall survival at 5 years was 0.746 (95% CI, 0.603, 0.843) in the dose-dense arm and 0.406 (95% CI, 0.265, 0.543) in the CHOP arm. This latter difference was statistically significant with a P value of 0.0062 (Fig. 3) . (Fig. 5) .
In the CHOP arm, a few more T cell lymphomas, primarily anaplastic large-cell lymphoma, were included. This difference was not statistically significant (Table 1 ). Because T cell lymphomas have a less favorable outcome than B cell lymphomas, we also analyzed our data when T cell lymphomas were excluded, but the survival benefit remained. In the dose-dense arm, one of the two patients with peripheral T cell lymphoma and one of the two patients with anaplastic large-cell lymphoma relapsed and 
ALCL anaplastic large-cell lymphoma, PTL-U peripheral T cell lymphoma unspecified subsequently died. In the CHOP arm, three of the six patients with peripheral T cell lymphoma and three of the six patients with anaplastic large-cell lymphoma relapsed and subsequently died (Table 4) . When analyzing the subgroups, the patient numbers get smaller and results are less robust. However, it seems to be unlikely that the small number patients that died from relapsed T cell lymphoma explains the survival benefit of the dose-dense therapy.
In the case of relapse, two patients in the dose-dense arm and five patients in the CHOP arm received stem-cell transplants. Rituximab was a part of the salvage treatment in two patients in the dose-dense arm and in one patient in the CHOP arm.
Response
The overall remission rate was 94.2% (49/52) and 86.3% (44/51) in the dose-dense and the CHOP arm, respectively. A CR was achieved in 39 (75%) patients and a CRu in four (7.7%) patients in the dose-dense arm. In the CHOP arm, 37 (72.5%) patients had a CR and none had a CRu. Only two patients (3.8%) progressed during therapy in the dosedense arm and seven (13.7%) in the CHOP arm. These differences did not reach statistical significance. One patient died in the dose-dense arm before an evaluation of the remission was possible.
Dose intensity
The planned and received chemotherapy doses for both arms are listed in Table 2 . The planned dose intensity for vincristine and the anthracyclines were comparable in both arms. The cyclophosphamide dose was higher in the CHOP arm, but ifosfamide was added to the dose-dense arm to compensate. In addition, etoposide and methotrexate were given in the dose-dense arm. The received dose intensity was somewhat lower than the planned dose intensity in the dose-dense arm. Toxicity Dose-dense therapy produced significantly more toxicity than standard therapy. Table 3 lists the side effects that were significantly different between the two arms. Because the blood samples were taken at different intervals (at least weekly intervals in the dose-dense arm and at least threeweekly intervals in the CHOP arm), the most severe toxicity for each treatment cycle was documented. Laboratory-documented toxicity, particularly hematologic toxicity, was higher in the dose-dense arm. In the dosedense arm, long-term peripheral neuropathy grades 1 and 2 were reported in three and two patients, respectively, lasting up to 3 years after the end of therapy. Myelodysplastic R rituximab, salvage salvage chemotherapy other than CEOP/IMVP, asct autologous stem-cell transplantation, DLBCL diffuse large B cell lymphoma, PB plasmablastic lymphoma, ALCL anaplastic large-cell lymphoma, PTCL peripheral T cell lymphoma rituximab-containing salvage therapy, and five patients had autologous stem-cell transplants (Table 4) .
Discussion
In this randomized, multicenter trial, we tested whether dose-dense therapy improved survival over standard treatment with CHOP. We demonstrated that dose-dense therapy significantly improved the absolute survival by 30% after 3 years and 34% after 5 years (Fig. 3) . Although survival is the most stable endpoint in clinical trials, some of our findings did not fit into the primary endpoint. The difference in the rate of remission and progression during therapy did not reach a statistically significant level. At the first glance, it is unclear how a better survival could be achieved without a difference in remissions. In the dosedense arm, only three of six PRs relapsed. In the CHOP arm, all seven PRs relapsed ( Table 4 ). The remissions were determined by CT scans, as PET scans were not generally available at the time of the study. Hence, we assume that the CR rate is misleading, and some of the PRs in the dosedense arm were CRs. None of the two progressing patients died in the dose-dense arm, while all seven progressive patients died in the CHOP arm. TTF was better for the dose-dense arm, although this difference did not quite reach statistical significance. Stem-cell transplantation or rituximab therapy, which are considered the most effective salvage treatments, do not explain this discrepancy since they were done in such low frequency (Table 4 ). The more likely explanation for the bigger difference in overall survival compared with TTF is that dose-dense therapy eradicates the most aggressive clones early on and relapses are easier to treat after dose-dense treatment. Unfortunately, we are not able to prove this assumption. However, from the patients' view, survival is the most important result; survival is the most reliable endpoint from the biostatisticians' view as well. The sample size was thoroughly calculated to verify the difference between dose-dense and CHOP therapy, but it is small relative to other clinical trials. We tested CEOP/IMVP-Dexa in two previous AGMT trials (NHL-1 and NHL-3). The 3-year survivals in these trials were 0.7212 and 0.7610, respectively. These results support reproducibility of the 3-year survival of 0.766 in the recent trial. The survival in the CHOP arm is comparable with those in other trials (Table 5) . However, in the German trial comparing CHOP14 with CHOP21, similar survival results were reported for the CHOP21 arm, despite an older population [22] , However, although the patients in our trial are positively selected regarding the age and IPI, comparisons between different trials must be interpreted with great caution because of unrecognized biases. Another concern might be that the dose-dense regimen is an over treatment for low-risk patients. Subgroup analysis in trials with small patient numbers is always problematic. However, patients with low or low-intermediate IPI have a survival benefit with dose-dense therapy (Fig. 5) .
A key question is whether patients in the dose-dense arm actually received more dose density than patients in the CHOP arm. The planned dose intensity was higher in the dose-dense arm than in the CHOP arm (Table 2 ). In addition, ifosfamide, etoposide, and methotrexate were given. On the other hand, dose reductions were more frequent in the dosedense arm. For patients over the age of 60, a 20% dose reduction was mandatory. However, 45% of cycles of the dose-dense therapy were delayed for not more than 1 day, and in 85% of cycles, the therapy intervals were shorter than 3 weeks. Dose was adjusted to toxicity. Patients without toxicity received the full dose. In other patients, the dose was reduced to a tolerable level. Thus all patients received the highest tolerable dose density.
Toxicity is one of the major concerns in chemotherapy treatment regimens. Not surprisingly, the dose-dense arm had significantly higher toxicity (Table 3) . However, most side effects subsided within a few weeks. Only neurotoxicity persisted up to 3 months after the dose-dense therapy. Myelodysplasia or leukemia was not observed. Treatmentrelated deaths were less frequent in the dose-dense arm. Apart from toxicity, dose-dense therapy is more cumbersome to apply, has higher costs, and requires more hospital or outpatients visits than CHOP. Considering the survival benefit of the dose-dense therapy, these disadvantages should be acceptable.
Other researchers have also shown that dose-dense regimens are more effective than CHOP. The superiority of ACVBP, a dose-dense regimen, was demonstrated for patients from 61 to 69 years of age 25 and at the least one adverse prognostic factor and for younger patients in stage I or II [24] . A British Group used PACEBOME in a dosedense manner and had a superior cause-specific survival than CHOP [18] . Finally, bi-weekly CHOP showed better survival in an elderly population in a German trial [22] . In none of these trials did the difference with standard CHOP reach a level of 34% as it did in our study (Table 5 ). In a patient population similar to the population in our study, a 2-year overall survival of 67% was achieved with VACOP-B [2] , a dose-dense regimen. However, VACOP-B has not been compared with CHOP in a randomized trial.
High-dose therapy with autologous stem-cell rescue was another promising attempt to overcome resistance and improve treatment outcome for aggressive non-Hodgkin's lymphoma. The results of this attempt were conflicting, and a recent comprehensive review of high-dose therapy in first-line treatment of aggressive non-Hodgkin's lymphoma failed to find an improvement [14] . The toxicity of highdose therapy prohibits subsequent cytotoxic therapy for a longer time period. If the high-dose therapy did not eradicate the last lymphoma cell, rapid regrowth of the lymphoma would take place, according to the Gompertzian model [20] .
Rituximab (R) has considerably changed the treatment of B cell lymphoma [5, 15, 21, 23] , but it was not available until after the recruitment for our study was completed. Chemotherapy without rituximab is no longer the standard treatment for diffuse large-cell lymphoma. Now, it is more important to determine if dose-dense therapy can improve on R-CHOP. The GELA Group is currently completing a randomized trial (LNH 03-6B) comparing R-CHOP21 to R-CHOP14. The results are eagerly awaited. The RICOVER60 trial could show that rituximab, when added to CHOP14, results in a better outcome [21] . We recently finished a phase II trial with dose-dense therapy and rituximab 375 mg/m 2 on days1 and 15. Comparing these patients with the patients in this NHL-5 trial, we observed a significant TTF and OS benefit of R-CEOP/IMVP compared to CHOP. R-CEOP/IMVP also results in a better, but to date, not statistically significant TTF and OS compared to the dose-dense arm in NHL-5. If we will find a statistically significant difference with longer follow-up, we will conduct a randomized trial comparing R-CHOP with R-CEOP/IMVP. Until proven otherwise, R-CHOP still remains the standard.
